source
- Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage failWhile Bausch + Lomb’s dual-action eye drops failed to outperform active comparators at day 29, the investigational asset showed significant superiority at day 15.BioSpace · 1h ago↗ source
- Why Biopharma Executives Should Hire an ‘Implementer’ to Turn Ideas into ActionLeadership Lab is a new column aimed at biopharma leaders facing real‑world pressures. In the opening piece, Michael Pietrack of Kaye/Bassman International argues that the most valuable hire for an…
- Regeneron halts Phase 1/2 uveitis antibody trial after safety concerns